AFP and hepatocellular carcinoma: The clinical accuracy of AFP-L3 as a biomarker for HCC is modest (sensitivity 39–65% and specificity 76–94%) [44], with nearly one third of early-stage HCC cases being missed when AFP is used alone [45].